Preparation of stable liquid and dried synthetic prothrombin time reagents
Patent 6733985 Issued on May 11, 2004. Estimated Expiration Date: May 19, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/13, Involving blood clotting factor (e.g., involving thrombin, thromboplastin, fibrinogen, etc.)562/576, Beta alanine per se or salt thereof562/561, Plural nitrogens536/65Propionate, butyrate or isobutyrate containing
A reagent for determining prothrombin time (PT) including a recombinant protein tissue factor, a mixture of synthetic phospholipids, and a beta, gamma, or delta amino acid stabilizing compound is described for monitoring extrinsic blood coagulation activities. The source for the recombinant protein tissue factor is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylphosphatidylserine (POPS). The particular formulation buffer used to dilute the lipidated tissue factor provides a reagent that is optionally dried without lyophilization and remains stable for at least about 2 weeks at 37 C as either a liquid or a dried powder. A method for preparing the improved PT reagent and a method of using the reagent to analyze blood PT is also provided.
Other References
Matsumoto Preventing freeze denature of milk or condensed milk-by adding an amino acid or its salt to the milk and storing in refrigerator Derwent-Acc-No.: 1981-24596D.*
Bach, Ronald R., “Initiation of Coagulation by Tissue Factor”, CRC Critical Reviews in Biochemistry 1988; 23(4): pp. 339-368.
Nemerson, Yale, Tissue Factor and Hemostasis, Blood 71; pp. 1-8. (Jan. 1988).
J. Philpott et al., “A Very Mild Method Allowing the Encapsulation of Very High Amounts of Macromolecules into Very Large (1000 nm) Unilateral Lipsomes”, Biochimica et Biophysica Acta; 734 137-143 (1983).
L.T. Mimms, et al., “Phospholipid Vesicle Formation and Transmembrane Protein Incorporation Using Octyl Glucoside”, Biochemistry, 20,833-840 (1981).
R. Bach, et al., “Factor VII Bonding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperativity by Phosphatidylserine”, Biochemistry, 25, 4007-4020 (1986).
George J. Broze, Jr. et al, “Purification of Human Brain Tissue Factor*” The Journal of Biological Chemistry, vol. 260, No. 20, issue of Sep. 15, 1985, pp. 10917-10920.
Marcie C. Coots et al. “A Factor V Inhibitor: In Vitro Interference by Calcium”, American Journal of Hematology, 1979,pp. 173-180.
Gregory Gregoriadis, Ph.D, Liposome Technology, vol. 1, Preparation of Liposomes. 1984, Chapter 11, pp. 139-161.
Freiburg Buchner et al. “Thrombosis Et Diathesis Haemorrhagica” 1965, pp. 393-395.
K.M. Brinkhous et al, “Thrombosis Et Diathesis Haemorrhagica”, vol. XXI, 1969, pp. 547-560.
Ernest Jawetz, et al. “Review of Medical Microbiology”, 1978, p. 86.
Jeffrey H. Lawson et al., “Cooperative Activation of Human Factor IX by the Human Extrinsic Pathway of Blood Coagulation*”, The Journal of Biological Chemistry, vol. 266, Jun. 15, 1991, pp. 11317-11327.
R. Bruce Martin, “Introduction To Biophysical Chemistry”, 1964, pp. 334-340.
Yale Nemerson, “The Phospholipid Requirement of Tissue Factor in Blood Coagulation”, The Journal of Clinical Investigation, vol. 47, 1968, pp. 72-80.
R.R.C. New, “Liposomes A Practical Approach”, Oxford University Press, 1990, pp. 17-18.
Linus Pauling, “College Chemistry, An Introduction Textbook Of General Chemistry”, Third Edition, 1950, pp. 640-641.
J. Phillipot et al. A Very Mild Method Allowing The Encapsulation Of Very High Amounts Of Macromolecules Into Very Large (1000 nm) Unilamellar Liposomes, Biochimica et Biophysica Acta, 1983, pp. 137-143.
R. Bruce Martin, “Introduction To Biophysical Chemistry”, 1964, p. 337.
Lawrence W. Powers, “Diagnostic Hematology Clinical and Technical Principles”, 1989, p. 482.
May 19, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
